Factors associated with interrupted pre-exposure prophylaxis (PrEP) in a Brazilian cohort: a brief communication.

IF 2.5 4区医学 Q3 INFECTIOUS DISEASES

AIDS Research and Therapy Pub Date : 2025-08-21 DOI:10.1186/s12981-025-00785-x

Patricia Matias Pinheiro, Nathalia Pedrosa Lima, Angelica Espinosa Miranda, Valbert Oliveira Costa Filho, Igor Pacheco Fiuza Romeiro, Hermano Alexandre Lima Rocha, Wildo Navegantes de Araújo

{"title":"Factors associated with interrupted pre-exposure prophylaxis (PrEP) in a Brazilian cohort: a brief communication.","authors":"Patricia Matias Pinheiro, Nathalia Pedrosa Lima, Angelica Espinosa Miranda, Valbert Oliveira Costa Filho, Igor Pacheco Fiuza Romeiro, Hermano Alexandre Lima Rocha, Wildo Navegantes de Araújo","doi":"10.1186/s12981-025-00785-x","DOIUrl":null,"url":null,"abstract":"Objective: To analyze factors associated with the discontinuation of pre-exposure prophylaxis (PrEP) for HIV among users in Brazil.Methods: An analytical case-control study was conducted using retrospective data (2018-2020) from PrEP users monitored by Brazil's Unified Health System (SUS) via the Medicines Logistics Control System (SICLOM). Cases (interrupted PrEP, n = 629) were matched 1:10 by sex at birth and age to controls (maintained PrEP, n = 6290). Logistic regression identified factors associated with discontinuation.Results: Factors significantly associated with PrEP discontinuation included previous anal lesions (adjusted Odds Ratio: 1.92; 95% Confidence Interval [CI]: 1.06-3.28; p = 0.022), active infections within the first 30 days of PrEP (aOR: 1.51; 95% CI 1.07-2.07; p = 0.014), and frequent medication forgetfulness (aOR: 1.48; 95% CI 1.19-1.84; p < 0.001). Not experiencing adverse effects during the first month was protective (aOR: 0.73; 95% CI 0.61-0.87; p < 0.001). The median time until discontinuation was 8 months.Conclusion: Early clinical experiences and adherence behaviors are critical for PrEP continuation. Enhanced support and monitoring, particularly in the first 30 days post-initiation, are pivotal to improve PrEP persistence in Brazil.","PeriodicalId":7503,"journal":{"name":"AIDS Research and Therapy","volume":"22 1","pages":"78"},"PeriodicalIF":2.5000,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12372239/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"AIDS Research and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12981-025-00785-x","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To analyze factors associated with the discontinuation of pre-exposure prophylaxis (PrEP) for HIV among users in Brazil.

Methods: An analytical case-control study was conducted using retrospective data (2018-2020) from PrEP users monitored by Brazil's Unified Health System (SUS) via the Medicines Logistics Control System (SICLOM). Cases (interrupted PrEP, n = 629) were matched 1:10 by sex at birth and age to controls (maintained PrEP, n = 6290). Logistic regression identified factors associated with discontinuation.

Results: Factors significantly associated with PrEP discontinuation included previous anal lesions (adjusted Odds Ratio: 1.92; 95% Confidence Interval [CI]: 1.06-3.28; p = 0.022), active infections within the first 30 days of PrEP (aOR: 1.51; 95% CI 1.07-2.07; p = 0.014), and frequent medication forgetfulness (aOR: 1.48; 95% CI 1.19-1.84; p < 0.001). Not experiencing adverse effects during the first month was protective (aOR: 0.73; 95% CI 0.61-0.87; p < 0.001). The median time until discontinuation was 8 months.

Conclusion: Early clinical experiences and adherence behaviors are critical for PrEP continuation. Enhanced support and monitoring, particularly in the first 30 days post-initiation, are pivotal to improve PrEP persistence in Brazil.

Abstract Image

查看原文本刊更多论文

巴西队列中与中断暴露前预防（PrEP）相关的因素：简短的交流

目的：分析巴西HIV使用者停止使用暴露前预防（PrEP）的相关因素。方法：采用巴西统一卫生系统（SUS）通过药品物流控制系统（SICLOM）监测的PrEP使用者的回顾性数据（2018-2020年）进行分析性病例对照研究。病例（中断PrEP， n = 629）按出生性别和年龄与对照组（维持PrEP， n = 6290） 1:10匹配。逻辑回归确定了与停药相关的因素。结果：与PrEP停药显著相关的因素包括既往肛门病变（校正优势比：1.92；95%可信区间[CI]: 1.06-3.28; p = 0.022）、PrEP前30天内的活动性感染（aOR: 1.51; 95% CI: 1.07-2.07; p = 0.014）、频繁用药遗忘（aOR: 1.48; 95% CI: 1.19-1.84; p）。结论：早期临床经验和依从性行为对PrEP的持续至关重要。加强支持和监测，特别是在开始后的头30天，对于提高巴西PrEP的持久性至关重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

AIDS Research and Therapy INFECTIOUS DISEASES-

CiteScore

3.80

自引率

4.50%

发文量

审稿时长

16 weeks

期刊介绍： AIDS Research and Therapy publishes articles on basic science, translational, clinical, social, epidemiological, behavioral and educational sciences articles focused on the treatment and prevention of HIV/AIDS, and the search for the cure. The Journal publishes articles on novel and developing treatment strategies for AIDS as well as on the outcomes of established treatment strategies. Original research articles on animal models that form an essential part of the AIDS treatment research are also considered